Propranolol and etodolac
Phase 3Small molecule
Propranolol and etodolac is one of 130 small molecule programs targeting Metastasis. It is currently in Phase 3.
4
Indications
4
Total Trials
2
Active Trials
129
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1063 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1Propranolol and etodolac
SSheba Medical Center
Phase 3
Gemzar
GGynecologic Oncology Group
Preclinical
Medrol
PfizerPreclinical
Byetta
AstraZenecaPreclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
ABI-007
Bristol-Myers SquibbPreclinical
Active Comparator
ModernaPreclinical
LDE225
NovartisPreclinical
Sulfonylureas
Eli LillyPreclinical
Thiazolidinediones
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer1 trial
Perioperative Intervention to Reduce Metastatic Processes in Pancreatic Cancer Patients Undergoing Curative Surgery
Unknown status·—·Phase 2·NCT03838029·210 enrolled
Colorectal Cancer1 trial
Metastasis1 trial
Colorectal Metastasis Prevention International Trial 2
Recruiting·—·Phase 2·NCT03919461·200 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Propranolol and etodolac. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- SSheba Medical Center